Principal Investigator
|
Title
|
Organization
|
Status
|
ID
|
Schwenkglenks, Matthias |
Health economic analysis alongside DROPIT trial |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Active |
4659722 |
Schwenkglenks, Matthias |
Gesundheitsökonomische Analyse von PsyYoung-Daten |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Active |
4643086 |
Schwenkglenks, Matthias |
SwissPandemic&AmR-Health Economy Awareness Detect (Flagship project), Subproject 4: Societal and Health Economics |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Active |
4642275 |
Schwenkglenks, Matthias |
Estimation of influenza hospitalisations from Medical Statistics of Hospitals |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
4605281 |
Schwenkglenks, Matthias |
Impact and economics of inclisiran in Switzerland |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
4602761 |
Schwenkglenks, Matthias |
Budget impact of GCSF biosimilars |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
4529725 |
Bhadhuri, Arjun |
Measurement properties of EQ-5D-3L and EQ-5D-5L in recording self-reported health status in older patients with substantial multimorbidity and polypharmacy |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
4522434 |
Schwenkglenks, Matthias |
Cost-effectiveness of novel ophthalmology drugs |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
4491703 |
Schwenkglenks, Matthias |
Cost-effectiveness of novel multiple sclerosis drug |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
4491692 |
Schwenkglenks, Matthias |
ENDOSCAPE, a clinically applicable non-viral gene delivery technology |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
4491519 |
Schwenkglenks, Matthias |
Regulierungsfolgenabschätzung zur Einführung eines Referenzpreissystems in der Schweiz |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
4485812 |
Schwenkglenks, Matthias |
Impact of targeted therapy in patients with metastatic lung cancer |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
4473765 |
Schwenkglenks, Matthias |
Kostenmodell Etanercept-Biosimilar |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
4354690 |
Schwenkglenks, Matthias |
Use of denosumab in different indications in Switzerland |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
4354689 |
Meier, Christoph R.; Schwenkglenks, Matthias |
Arzneimittelreport Schweiz |
Departement Public Health / Pharmazeutische Medizin (Szucs), Departement Pharmazeutische Wissenschaften / Klinische Pharmazie/Spitalpharmazie (Meier) |
Completed |
3706169 |
Schwenkglenks, Matthias |
Pill Protect: health-economic performance characteristics and implications for health care funding |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
3567316 |
Schwenkglenks, Matthias |
Cost-effectiveness of hyperkalemia treatment |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
3529269 |
Schwenkglenks, Matthias |
Cost of HCV treatment in Switzerland |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
3511583 |
Schwenkglenks, Matthias |
OPERAM: Optimising PharmacothERApy in the Multimorbid elderly |
Departement Public Health / Pharmazeutische Medizin ECPM, Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
3032139 |
Schwenkglenks, Matthias |
Cost-effectivness of chronic heart failure treatment |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
3008122 |